MedTrace Logo

TMS for Exposure Therapy Resistant OCD

NCT05331937 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-03-04

No results posted yet for this study

Summary

TETRO is a multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months in 250 adult (18 years and older) OCD patients who show no/insufficient response to ERP, aiming to establish the cost-effectiveness of low frequency (1 Hz) rTMS to the pre-SMA (compared to sham rTMS to the pre-SMA) as adjuvant treatment to exposure with response prevention (ERP). The treatment consists of 4 times/week rTMS combined with ERP for at least 5 weeks (20 sessions), with optional extension phase of 1 or 2 weeks (maximum of 28 sessions in total).

Conditions

  • 1 Hz Real rTMS to the Pre-SMA
  • 1 Hz Sham rTMS to the Pre-SMA

Interventions

COMBINATION_PRODUCT

repetitive transcranial magnetic stimulation (rTMS)

rTMS (real versus sham) is used as adjuvant to ERP

Sponsors & Collaborators

  • GGZ inGeest

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • ProPersona

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Mondriaan

    collaborator UNKNOWN

  • Neurocare

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-16
Primary Completion
2027-12-01
Completion
2027-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05331937 on ClinicalTrials.gov